Gain Therapeutics, Inc. (GANX) - Dilution Analysis

10-Q filing | 42.2M shares outstanding

10-K filing | 42.1M shares outstanding

10-Q filing | 35.0M shares outstanding

S-3/A filing: This is an S-3/A filing for Gain Therapeutics, Inc., registering securities for sale.

10-Q filing | 30.3M shares outstanding

8-K filing: Gain Therapeutics, Inc. entered into an underwriting agreement to offer 4,501,640 shares of common stock and warrants to purchase 2,250,820 shares for gross proceeds of approximately $7.0 million. ($7.0M proceeds)

S-3 filing: This is an S-3 filing for a shelf registration of common and preferred stock by Gain Therapeutics, Inc.

10-Q filing | 28.7M shares outstanding

10-K filing | 27.1M shares outstanding

10-Q filing | 26.5M shares outstanding

10-Q filing | 25.2M shares outstanding

8-K filing: Gain Therapeutics, Inc. entered into an underwriting agreement to sell 7,116,547 shares of common stock and pre-funded warrants exercisable for up to 1,031,602 shares of common stock at $1.35 per share and $1.3499 per pre-funded warrant, respectively, with net proceeds expected to be approximately $10.1 million. ($11.0M proceeds)

10-Q filing | 18.0M shares outstanding

10-K filing | 16.2M shares outstanding

S-1 filing: This S-1 filing details the resale of common stock and shares issuable upon exercise of warrants, including private placements and public offerings.

8-K filing: Gain Therapeutics, Inc. entered into an underwriting agreement for a public offering of 2,213,044 shares of common stock and warrants to purchase 1,106,522 shares, and a concurrent private offering of 744,026 shares of common stock, pre-funded warrants for 1,756,062 shares, and warrants to purchase 2,500,088 shares. ($9.4M proceeds)

10-Q filing | 12.7M shares outstanding

10-Q filing | 12.4M shares outstanding

10-Q filing | 11.9M shares outstanding

10-K filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

S-3/A filing: Consent to reference to Ernst & Young AG as experts in the Registration Statement (Form S-3) for the registration of up to $100,000,000 of Common Stock, Preferred Stock, Debt Securities and Warrants.

S-3 filing: Registration statement for the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $100.0 million of our common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and a sales agreement prospectus supplement that covers the offering, issuance and sale by us of up to a maximum aggregate offering price of $16.0 million of our common stock that may be issued and sold under a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co.

10-Q filing | 11.9M shares outstanding

10-K filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

8-K filing: Matthias Alder was appointed Chief Operating Officer of Gain Therapeutics, Inc. effective October 15, 2021, and will receive a stock option grant of 200,000 shares and restricted stock unit grants of 200,000 shares.

10-Q filing | 11.9M shares outstanding

10-Q filing | 11.9M shares outstanding

8-K filing: Gain Therapeutics, Inc. closed its initial public offering of 3,636,364 shares of its common stock at $11.00 per share on March 22, 2021, and also amended and restated its Certificate of Incorporation and Bylaws effective as of March 17, 2021. ($40.0M proceeds)

S-1/A filing: The filing relates to an offering of common stock by Gain Therapeutics, Inc. with 3,636,364 shares offered and an additional 545,454 shares available under the underwriter's option. The company intends to use the net proceeds from this offering to advance its lead programs in preclinical studies and into clinical trials, to advance our discovery and candidate selection stage programs and for general corporate purposes.

S-1/A filing: The company is offering 3,636,364 shares of common stock at an assumed initial public offering price of $11.00 per share. The underwriters have the option to purchase an additional 545,454 shares of common stock. The company intends to use the net proceeds from this offering to advance its lead programs in preclinical studies and into clinical trials, to advance its discovery and candidate selection stage programs and for general corporate purposes.

S-1 filing: This is an S-1 filing for an initial public offering of common stock, with an underwriter option to purchase additional shares, and includes information regarding a previous private placement of Series B Preferred Stock.